Biopharmaceutics Drug Disposition Classification System

ALAN TALEVI; CAROLINA BELLERA

The ADME Encyclopedia. A Comprehensive Guide on Biopharmacy and Pharmacokinetics

Springer Nature

Lugar: Basignstoke; Año: 2022;

The Biopharmaceutic Drug Disposition Classification System (BDDCS) is a revision of the Biopharmaceutics (or Biopharmaceutical) Classification System (BCS) that may be useful to predict routes of elimination and to foresee the effects of absorptive and efflux transporters on oral absorption and drug-drug interactions [1]. It was conceived to predict the disposition characteristics of novel drugs (new molecular entities, NME). The fundamental idea of this derivative classification system is to replace permeability in the BCS by the extent of metabolism (by recognizing the strong correlation between these two properties). A central notion intrinsic to the BDDCS is that it recognizes the influence of drug transporters on drug bioavailability and disposition, and their impact is assessed across the different categories that compose the system. While this might be obvious today, at the time the BDDCS was devised the role of transporters in drug pharmacokinetics was quite overlooked. The arguments provided in the context of the BDDCS have influenced posterior regulatory guidelines, which have increasingly recognized the impact of drug transporters on drug pharmacokinetics.